학술논문

New Approaches in Immunotherapy of Behçet Disease
Document Type
article
Source
Advanced Pharmaceutical Bulletin, Vol 3, Iss 1, Pp 9-11 (2013)
Subject
Behçet disease
Neutrophil
Immunotherapy
Monoclonal antibodies
IL-21
IL-17
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
2228-5881
2251-7308
Abstract
Behçet Disease (BD) is an autoimmune disorder with recurrent ocular, vascular, central nervous system, articular, mucocutaneous, and gastrointestinal manifestations with unclear etiology and pathogenesis. The further characterization of inflammatory features of Behçet’s disease may eventually lead to development of better treatment options. Clinical and laboratory observations suggested an important role of IL-17, IL-21 and neutrophil-mediated process in the pathogenesis of BD. New therapeutic modalities target specific and nonspecific suppression of the immune system. The various non-specific immunosuppressive drugs, used either alone or in combinations, frequently fail to control inflammation or maintain remissions. Due to encouraging clinical results (i.e. Antigenic specification, prolonged survival with acceptable levels of toxicity); antibody-based drugs could be effective for the clinical management of Behçet’s disease.